HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MYGN
Myriad Genetics, Inc.
MYGN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MYGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Under pressure |
MYGN's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MYGN PE Valuation
MYGN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over MYGN on the outlook, with more favorable revenue and profitability expectations.
MYGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect MYGN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MYGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$2.96 |
| Q2 2026 | -$1.20 | +$3.08 |
| Q1 2026 | -$4.31 | -$3.19 |
| Q4 2025 | -$3.95 | -$2.54 |
| Q3 2025 | -$4.33 | -$3.05 |
| Q2 2025 | -$4.28 | -$2.49 |
| Q1 2025 | -$1.12 | +$1.68 |
| Q4 2024 | -$1.41 | +$1.77 |
MYGN is still losing money, but far less than before: $1.37 per share over the past year, against $4.33 at its worst in late 2025.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MYGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MYGN on profitability, with a higher operating margin.
MYGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $202.7M | -1.5% |
| Q2 2026 | $190.7M | -11% |
| Q1 2026 | $200.4M | +2.3% |
| Q4 2025 | $209.8M | -0.4% |
| Q3 2025 | $205.7M | -3.6% |
| Q2 2025 | $213.1M | +0.8% |
| Q1 2025 | $195.9M | -3.1% |
| Q4 2024 | $210.6M | +7.1% |
MYGN's revenue grew through 2023 and has held roughly level since: $203M last quarter, down 1.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -8.3 points |
| Q2 2026 | -20% | +134 points |
| Q1 2026 | -15% | -0.5 points |
| Q4 2025 | -2.7% | +16 points |
| Q3 2025 | -11% | -1.9 points |
| Q2 2025 | -154% | -137 points |
| Q1 2025 | -15% | -1 points |
| Q4 2024 | -19% | -2.5 points |
MYGN's operating margin was −20% last quarter, down 8.3 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MYGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
MYGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5M | -131% |
| Q2 2026 | -$8.3M | +$5.3M |
| Q1 2026 | -$15.7M | +$600K |
| Q4 2025 | $10.6M | +61% |
| Q3 2025 | $21.1M | +2914% |
| Q2 2025 | -$13.6M | -623% |
| Q1 2025 | -$16.3M | +$2.3M |
| Q4 2024 | $6.6M | +$61.3M |
MYGN has burned cash in most quarters: −$20M over the past year, against −$2M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MYGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MYGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +900K shares |
| 1 year | +2.8% | +2.6M shares |
| 3 years | +17% | +13.8M shares |
| 5 years | +17% | +14.2M shares |
| Available history | +29% | +21.3M shares |
MYGN has 96M diluted shares, up 2.8% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MYGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 3.3x | Elevated |
MYGN's net debt is about 3.3 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MYGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 80.3 | Overbought |
MYGN's weekly RSI is 57 (neutral) and its Stochastic is 80 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MYGN PE vs Healthcare Sector
MYGN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MYGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.10 | 11% above |
| 20 week MA | $4.52 | 26% above |
| 50 week MA | $4.88 | 16% above |
| 100 week MA | $6.48 | 12% below |
| 200 week MA | $13.8 | 59% below |
MYGN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MYGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.8 | $18.4 | -31% |
| 2021 | $18.4 | $27.3 | +48% |
| 2022 | $27.3 | $15.6 | -43% |
| 2023 | $15.6 | $19.1 | +22% |
| 2024 | $19.1 | $13.4 | -30% |
| 2025 | $13.4 | $6.48 | -52% |
| 2026 YTD | $6.48 | $5.68 | -12% |
MYGN has the edge over HIMS on returns for 2026, with the stronger performance.